Lumiracoxib inhibits cyclo-ygenase 2 completely at the 50 mg dose: Is liver toxicity avoidable by adequate dosing?

Research output: Contribution to journal › Letter › Contributed › peer-review

Contributors

  • B. Hinz - , University of Rostock (Author)
  • B. Renner - , Institute of Clinical Pharmacology, Friedrich-Alexander University Erlangen-Nürnberg (Author)
  • O. Cheremina - , Friedrich-Alexander University Erlangen-Nürnberg (Author)
  • D. Besz - , Friedrich-Alexander University Erlangen-Nürnberg (Author)
  • O. Zolk - , Friedrich-Alexander University Erlangen-Nürnberg (Author)
  • K. Brune - , Friedrich-Alexander University Erlangen-Nürnberg (Author)

Details

Original languageEnglish
Pages (from-to)289-291
Number of pages3
JournalAnnals of the rheumatic diseases
Volume68
Issue number2
Publication statusPublished - Feb 2009
Peer-reviewedYes

External IDs

PubMed 19139209
ORCID /0000-0003-0845-6793/work/139025259

Keywords

ASJC Scopus subject areas